Home084990 • KOSDAQ
Helixmith Co Ltd
₩2,845.00
Jan 14, 2:12:26 AM GMT+9 · KRW · KOSDAQ · Disclaimer
StockKR listed security
Previous close
₩2,900.00
Day range
₩2,820.00 - ₩2,940.00
Year range
₩2,500.00 - ₩7,440.00
Market cap
131.13B KRW
Avg Volume
73.49K
P/E ratio
-
Dividend yield
-
Primary exchange
KOSDAQ
Market news
Financials
Income Statement
Revenue
Net income
(KRW)Sep 2024Y/Y change
Revenue
1.80B65.09%
Operating expense
5.81B-30.08%
Net income
-3.79B54.16%
Net profit margin
-210.4772.24%
Earnings per share
EBITDA
-3.97B24.02%
Effective tax rate
Total assets
Total liabilities
(KRW)Sep 2024Y/Y change
Cash and short-term investments
70.45B-16.48%
Total assets
149.90B-34.10%
Total liabilities
6.08B-79.04%
Total equity
143.83B
Shares outstanding
46.05M
Price to book
0.93
Return on assets
-8.32%
Return on capital
-8.66%
Net change in cash
(KRW)Sep 2024Y/Y change
Net income
-3.79B54.16%
Cash from operations
-4.52B7.87%
Cash from investing
32.00B121.76%
Cash from financing
-6.68M99.86%
Net change in cash
27.80B474.69%
Free cash flow
523.28M107.32%
About
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Founded
Nov 1996
Employees
72
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu